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Genistein induces adipogenesis but inhibits leptin 
induction in human synovial fibroblasts 
Biserka Relic\ Mustapha Zeddou2, Aline Desoroux1, Yves Beguin 2, Dominique de Seny1 and Michel G Malaise1 
It was shown recently that synovial fibroblast transformation into adipocytes reduced the expression of interleukin-6 
(lL-6) and IL-8. However, the synovial fibroblast adipogenesis was inhibited in inflammatory conditions induced 
by the tumor necrosis factor-a (TNF-IX). Furthermore, adipogenesis is often accompanied by leptin production, a 
proinflammat9ry adipokine in rheumatic diseases. In this study, we tested the phytohormone genistein for adipogenic 
and anti-inflammatory properties on human synovial fibroblasts. Results showed that genistein was able to transform 
synovial fibroblasts into adipocytes that expressed perilipin-A and produced adiponectin, but not leptin. Furthermore, 
genistein, enhanced glucocorticoid-mediated synovial fibroblast adipogenesis and, in parallel, downregulated 
glucocofticoid-induced leptin and leptin receptor. Endogenous and TNF-a-induced expressions of IL-6, IL-8, p38, p65 and 
Ç/EBP-jl were also downregulated by genistein, showing its anti-inflammatory properties. Peroxisome proliferator-
activated receptor-y (PPAR-y) agonist, rosiglitazone, had a synergic effect on genistein-induced adipogenesis, whereas the 
non-active tyrosine kinase inhibitor, daidzein, had a significantly inferior adipogenic activity than genistein. The Janus 
kinase-2 tyrosine kinase inhibitor, AG 490, mimicked the anti-Ieptin effect of genistein. These results showed that 
genistein-induced adipogenesis involves PPAR-y induction and tyrosine kinase inhibition. In conclusion, genistein, alone 
or cou pied with glucocorticoids, have both adipogenic and anti-inflammatory effects on synovial fibroblasts. 
Laboratory Investigation (2009) 89, 811-822; doi:10.1038/labinvest.2009.41; published on li ne 11 May 2009 
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ln rheumatic diseases, such as osteoarthritis (OA) and 
rheumatoid arthritis (RA), synovial tissue proliferates and 
Becomes the site of inflammation. Synovial proliferation and 
ihflammation lead to chondrocyte apoptosis, cartilage da-
thage and joint dysfunction. 1 Indeed, cadherin-ll k/o mice 
that form defective synovium are more resistant to experi-
rbentally induced arthritis.z Recently, synovial fibroblasts 
Jere recognized as multipotent ceUs that can differentiate 
into osteocytes, chondrocytes and adipocytes.3-6 In addition, 
synovial fibroblasts were shown to express specific markers of 
bone marrow-derived multipotent stem ceUs (MSCs), such as 
CD-lOS, CD-90 and CD_73.3,7 Among the different sources 
of MSCs, such as bone marrow, skeletal muscle and adipose 
tissue, synovium was recognized as a potent source. 8 
Furthermore, synovial MSCs were shown capable of rabbit 
cartilage repair. 9 These results indicated that synovium re-
presents a precious source of MSCs, and also opened 
new approaches for combating synovial inflammation, by 
interfering with signaling pathways involved in MSC differ-
entiation. 
Synovial fibroblast transformation into adipocyte-like cells 
was shown in vitro in the presence of the synthetic peroxi-
sorne proliferator-activated receptor-y agonist, 
troglitazone.6 These adipocyte-like cultures expressed less 
interleukin-6 (IL-6) and IL-8 than control ecUs, but adipo-
genesis was inhibited by the tumor l1eGOSiS factor-ex 
(TNF-a), suggesting that in inl1ammatory conditions, ceIls 
may continue to pro duce high levels of IL-o and IL-8. In 
addition, adipogenesis is associated with the production of 
leptin, an adipokine thought to be proinflammatory in both 
OA and RA. IO- 13 To that purpose, we searched for the PPAR-
y agonist(s) having anti-inflammatory propcrties in the 
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presence of TNF-IX. Three PPAR-y agonists were tested, 
namely the synthetic rosiglitazone, the precursor of natural 
PPAR-y agonist 15d-PGJ2, prostaglandin D2 (PGD2) and the 
plant hormone, genistein. 14,15 The results showed that 
TNF-IX-stimulated synovial fibroblast cultures expressed high 
levels of IL-6 and IL-8, treated with PGD2 or not. However, 
we showed that genistein downregulated both endogenous 
and TNF-IX-induced IL-6 and IL-8 in synovial fibroblasts. 
Rosiglitazone was also able to downregulate TNF-IX-induced 
IL-6, but significantly less th an genistein. 
We also showed that genistein, alone or in concerted action 
with rosiglitazone or glucocorticoids, induced synovial fibro-
blast adipogenesis. Furthermore, we observed that despite 
their ability to downregulate TNF-IX-induced IL-6 and IL-8, 
glucocorticoids induced marked leptin and leptin receptor 
expression in synovial fibroblasts. Genistein downregulated 
glucocorticoid-induced lep tin and leptin receptor expression. 
As lep tin has been recognized as proinflammatory for rheu-
matie diseases, JO,11 these results suggest that concomitant 
application of genistein and glucocorticoids may promote 
their anti-inflammatory properties. 
MATERIALS AND METHODS 
Synovial Fibroblast Isolation, Ce" Culturing and 
Adipogenesis Induction 
The synovial tissue was obtained from OA, RA and traumatic 
patients not having rheumatoid diseases, during joint re-
placement. Informed consents were obtained, and experi-
ments were approved by the ethics committee of our 
academic hospital (CHU, Liège, Belgium). Synovial fibro-
blasts were isolated as eXplained earlier. 16 Cells were cultured 
in the DMEM medium (Cambrex Bio Science, Walkersville, 
MD, USA), with L-glutamine (2 mM), streptamycin (l00 mg/ 
ml) and penicillin (100 U / ml) (Bio Whittaker, Walkersville, 
MD, USA), and supplemented with 10% fetal bovine serum 
(Lonza, Basel, Switzerland) for at least three passages before 
being used. Experiments were carried out in the DMEM 
medium lacking phenol red (Cambrex Bio Science), supple-
mented with 10% charcoal-stripped fetal bovine serum. Cells 
(5 x 104/0.5 ml of medium) were seeded in 24-well plates 
(BD Biosciences, San Jose, CA, USA) in triplicate. On the 
second day of culture, cells were stimulated with rosiglita-
zone, genistein, SB 203580, tyrphostin AG 490 (Alexis Corp., 
San Diego, CA, USA), PGD2 (Cayman Chemical, Ann Arbor, 
MI, USA) and/or dexamethasone, prednisolone, cortisone, 
17-j3-estradiol, N-acetyl cysteine (NAC) or daidzein (Sigma-
Aldrich, St Louis, MI, USA), in the presence or absence of 
TNF-IX. The medium was changed and ceUs were re-stimu-
lated every 6 days. Cells were harvested after 1-4 weeks. The 
synovial fibroblast origins used for experiments were 
Figure la: OA patient, Figure lb: traumatic patient, Figure 
2a-d: RA patient, Figure 2e: traumatic patient, Figure 2f: OA 
patient, Figure 3a: RA patient, Figure 3b: Patient 1: traumatic, 
Patient 2: OA, Patient 3: RA, Patient 4:0A. Figures 4 and 5: 
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OA patients, Figure 6a-d: OA patient, Figure 6e: OA patient, 
Figure 6f: RA patient, Figures 7-9: OA patients. 
Oil Red Staining 
CeUs were fixed in 4% paraformaldehyde in PBS for 15 min 
and then washed with PBS. For staining, an oil red stock 
solution (5 g/l of isopropanol) was diluted with distilled 
water in a 4:6 ratio. Staining was performed for at least 1 h at 
room temperature. Before microscopy, ceUs were washed 
with distilled water. 
Microscopy 
Photos were captured using a digital sight camera (2 MV) 
under the inverted microscope Eclipse TSI00 (Nikon 
Instruments Inc., Melvile, NY, USA), using NIS-Elements 
Basic Research software (Nikon Instruments Inc.) and 
objectives with phase contrast. 
ELISA 
Prote in concentrations were determined in the ceU super-
natant using commercial kits IL-6, IL-8 (BioSource, Fleurus, 
Belgium), leptin and adiponectin (R&D Systems, Minneapolis, 
MN, USA) according to the manufacturer's instructions. 
Western Blot 
Cel!s were col!ected, lysed and total proteins separated by 
SDS-PAGE as explained earlier. 16 Membranes were incubated 
with perilipin-A (Sigma-Aldrich), PPAR-y (E-8), ERKl 
(K-23), p-ERK (E-4), C/EBP-j3 (0198), Ob-R (B-3) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), p38, p38 Thr80/Tyr82 
(Cel! Signaling, Beverly, MA, USA) and NF-KB p65 (Upstate 
Biology, Lake Placid, NY, USA) antibodies for 1-3 h at room 
temperature. Western blots were shown with 1:2000 diluted 
anti-mouse or anti-rabbit (DAKO NS, Glostrup, Denmark) 
antibodies and ECL chemiluminescent reagents (Amersham 
Biosciences, Little Chalfont, Buckinghamshire, UK). 
Flow Cytometry Analyses 
Simple staining was performed with fluorescent-conjugated 
antibodies. The following monoclonal, PE-conjugated anti-
bodies were used: anti-CD-73, anti-CD-90, anti-I05, anti-
HLA-DR, anti-CD-80 and anti-CD-45 (BD Biosciences). The 
phenotype was performed on (1-5) x 105 synovial fibro-
blasts, cultured earlier for three passages. The fluorescence 
intensity was analyzed on FACSvantage with Cell Quest 
software (BD Biosciences). 
Chip (Chromatin Immunoprecipitation) Assay 
Chip (chromatin immunoprecipitation) assay was performed 
on the basis of Q2ChIP protocol and The Low Cel! ChIP Kit 
(Diagenode, Liege, Belgium),l7 with a few modifications. 
Synovial fibroblasts were seeded 24 h before the experiment 
in 10-cm dishes (1.5 x 106/5 ml). The next day, cel!s were 
treated with genistein for 3 h, followed by 15 min of TNF-IX 
stimulation. Protein DNA cross-Iinking was performed 




a HLA-DR CD-80 CD-45 
80 80 80 
0.08 % 0.17 % 
If) ~ ~ ë c C 
:l ::J ::J 
0 0 0 
ü ü ü 
0 0 0 
10° 101 102 103 104 10° 10 1 102 103 104 10° 10 1 102 103 104 
CD-73 CD-90 CD-105 
80 80 80 
93.22 % 98.99 % 6015 % 
If) ~ ~ \~ ë c C :l ::J ::J 0 0 0 \. ü ü ü 
0 0 0 
10° 10 1 102 103 104 10° 10 1 102 103 104 10° 101 102 103 104 
b 
Control Rosiglitazone Genistein PGD2 
Figure 1 Genistein, rosiglitazone and PGD2 induce synovial fibroblasts adipogenesis. (a) Flow cytometry diagrams showing the expression profile of 
synovial fibroblasts harvested after three passages and stained for surface molecules as indicated. The percentage of positive cells was calculated and 
shown in each diagram. (b) Oil-red-stained adipocyte-like single cell in the 3-week-old synovial fibroblast cultures treated with different PPAR-}' agonists 
only as indicated. Photos were taken under an inverse microscope at magnification x 40. 
directly in the culture medium with 10/0 formaldehyde, at 
37°C, for 10 min. After being washed thrice with cold PBS 
containing complete protease inhibitor cocktail (Roche, 
Mannheim, Germany), cells were scraped on ice, recuperated 
by centrifugation (l500r.p.m., 10 min, 4°C) and dissoived in 
130)11 oflysis buffer (50 mM TRIS-HCl, pH8, 10 mM EDTA, 
10/0 SDS, l mM PMSF and protease inhibitor cocktail). So-
nication was performed for 3 min, with 30-s pauses, using the 
maximum power of Bioruptor (Diagenode). Chromatin was 
diluted with 870)11 RIPA buffer (10 mM Tris-HCl, pH 7.5, 
1 mM EDTA, 1% Triton X-lOO, 0.10/0 SDS, Na-deoxycholate, 
100 mM NaCl), centrifuged for 5 min at 12000 r.p.m. and 
supernatant recuperated. For immunoprecipitation, 100)11 of 
diluted chroma tin was incubated overnight (4 oC, at 
20 r.p.m.) in 0.2-ml tubes with 10)11 of magnetic protein A 
beads (Dynabeads, Invitrogen, Carlsbad, CA, USA) that had 
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been pre-covered for at least 2 h with NF-/(B p65 (A) X 
(Santa Cruz) or CIEBP-{J CLAP) (Cell Signaling) antibodies. 
IgG antibodies were used for the negative control. Beads were 
washed thrice with RIPA buffer, dissolved in TE buffer 
(l0 mM Tris-HCl, pHS, 10 mM EDTA) and transferred into 
Eppendorf tubes. TE was discarded and DNA was purified by 
boiling the beads for 10 min with 100)11 of 10% Chelex-lOO 
slurry (Bio Rad, Hercules, CA, USA), 1 h of proteinase-K 
treatment (200 )1g/ml) at 55 oc, followed by 10 min of sam pie 
boiling. DNA containing supernatant was recuperated and 
used for PCR analyses. Input DNA was purified in the 
same way from the 100)11 of starting material used for 
immunoprecipitation. Standard and real-time PCR were 
performed using the following IL-8 promoter primer pairs: 
5' -GGCCATCAGTTGCAAATCG-3' (forward) and anti-sense 
5'-AGTGCTCCGGTGGCTTTTT-3' (reverse). Real-time PCR 
813 
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Figure 2 Genistein inhibits TNF-O'-induced IL-6 and IL-8. (a-f) ELISA measured adiponectin (panel a), leptin (panel b), IL-6 (panels c, e and f) and IL-8 (panel 
d) production in cell supernatant. Synovial fibroblasts, obtained from RA (panels a-dl, traumatic (panel e) or OA (panel f) patient, were treated for 3 weeks 
with different PPAR-y agonists or p38 inhibitor, SB 203580, in the presence or absence of TNF-C(, as indicated. *A, statistically different from control cells; *B, 
statistically different from genistein-treated cells; *C, statistically different from rosiglitazone-treated cells; *D, statistically different from PGD2-treated cells; 
'E, statistically different from TNF-C(-treated cells; *F, statistically different from TNF-C(- and rosiglitazone-treated cells. 
was performed in triplicate using the SYBR green PCR mix 
(Applied Biosystems) and the ABI Prism 7000 Sequence 
Detection System (ABI Prism, Foster City, CA, USA). 
814 
Statistics 
P-values were obtained using the Mann-Whitney U-test and 
were considered as significant when < 0.05. 
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Figure 3 Genistein inhibits p38, C/EBP and NF-KB pathways. (a) Western blots showing expression of adipocyte marker, perilipin-A, phosphorylated p38 (P-
p38), p38, p65 units of NF-IcB and LAP form of C/EBP-P in synovial fibroblasts extracts. Cells were treated for 4 weeks with different PPAR-y agonists, in the 
presence or absence of TNF-C(, as indicated. ERK 1/2 expression was used as control. (b and c) ChlP analyses performed with p65 or C/EBP-P antibodies on 
the synovial fibroblast pre-treated with genistein or not (50 pM), then 15 min of TNF-C( (10 ng/ml) treatment. DNA was amplified by standard (panel b) or 
real-time PCR (panel c) with IL-8 promoter primers. Input DNA was diluted in a ratio of 1:10. IgG antibodies were used as negative control. 
RESULTS 
Genistein Induces Synovial Fibroblast Adipogenesis and 
Downregulates both Endogenous and TNF-oc-Induced 
IL-6 and IL-S 
Isolated hum an synovial fibroblasts that were cultured earlier 
for at least three passages were used. FACS analyses con-
www.laboratoryinvestigation.ol'g 1 Laboratory Investigation 1 Volume 89 July 2009 
firmed that synovial fibroblasts expressed mesenchymal stem 
cel! markers, CD-73, CD-90 and CD-lOS (Figure 1 a). Cells 
were negative for HLA-DR, CD-SO, CD-4S (Figure la), as 
well as for CD-3 and CD-3l (data not shown). Synovial 
fibroblasts were stimulated with genistein, rosiglitazone or 
PGD2 in the presence or absence of TNF-iX for 3-4 weeks. 
815 
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Figure 4 Genistein and rosiglitazone induce adipogenesis in synergism. (a-c) Synovial fibroblasts were cultured with genistein or rosiglitazone only, or both 
substances simultaneously, at indicated concentrations, for 4 weeks. (Panel a) Oil-red-stained ce Ils. Photos were ta ken under an inverse microscope at 
magnification x 20. (Panel b) ELISA measured adiponectin production in cell supernatant. *A, statistically different from control cells; *B, statistically 
different from genistein-treated cells; *C, statistically different from rosiglitazone-treated cells. (Panel c) Western blots showing perilipin-A and PPAR-y 
expressions. ERK 1/2 expression was used as control. 
Adipocyte-like ceUs (Figures lb and 4a) that produced 
adiponectin (Figure 2a) emerged in cultures treated with 
genistein or rosiglitazone. These fat droplets stained po si-
tively with oil red (Figures lb and 4a) and did not pro duce 
leptin (Figure 2b). PGD2 induced mainlysebum-like drop lets 
816 
(Figure lb) and small amounts of adiponectin (Figure 2a) 
and leptin (Figure 2b). Both kinds of droplets expressed 
perilipin-A, inhibited by TNP-IX (Figure 3). TNP-IX also in-
hibited genistein- and rosiglitazone-induced adiponectin 
production, as weIl as PGD2-induced leptin production 
Laboratory Investigation 1 Volume 89 July 2009 1 www.laboratoryil1l1esligation.org 
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Figure 5 Effects of 17-fJ-estrogen, daidzein and N-acetyl cysteine (NAC) on 
synovial fibroblast adipogenesis. (a-c) ELISA measured adiponèctin 
production in cell supernatant. (Panel a) Synovial fibroblasts were treated 
for 4 weeks with genistein, rosiglitazone or simultaneously with 
rosiglitazone and 17-/l-estrogen, or rosiglitazone and genistein, al indicated 
concentrations. *A, statistically different From control cells; *B, statistically 
different From genistein-treated cells; *C, statistically different From 
rosiglitazone- and genistein-treated cells. (Panel b) Synovial fibroblasts 
were treated for 4 weeks with genistein or daidzein. *A, statistically 
different From control cells; *B, statistically different From genistein-treated 
cells. (Panel c) Synovial fibroblasts were treated for 3 weeks with genistein, 
NAC or simultaneously with genistein and NAC. *A, Statistically different 
From control cells; *B, statistically different From genistein-treated cells. 
(Figure 2a and b). Genistein, but not rosiglitazone or PGD2, 
at commonly used concentrations (10 j.lM), downregulated 
both endogenous and TNF-IX-induced production of IL-6 
and IL-8 (Figure 2c and dl. However, at high concentrations, 
rosiglitazone (50 pM) also downregulated TNF-IX-induced 
1L-6 production, but its effect was statisticaIly inferior com-
pared with that of genistein (Figure 2e and f). High con-
centrations of PGD2 could not be tested because they 
induced synovial fibroblast death (results not shown). The 
genistein effect was mimicked partially by p38 inhibitor, SB 
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203580, suggesting that genistein effect may involve p38. 
Similar results were obtained with synovial fibroblasts 
originating from the synovium of RA (Figure 2a-d), OA 
(Figure 2f) or traumatic patients (Figure 2e). These results 
showed that genistein has both adipogenic and anti-in-
flammatory effects on synovial fibroblasts. 
Genistein Inhibits Endogenous and TNF-IX-Induced p3a, 
C/EBP and NF-K8 Pathways 
As both genistein and p38 inhibitor, SB203580, inhibited 
endogenous and TNF-IX-induced synovial fibroblasts 1L-6 
and IL-8 production (Figure 2c and dl, and because pro-
moters ofIL-6 and IL-8 have binding sites for both C/EBP-j3 
and NF_KB,18,19 we have tested the effect of TNF-IX and 
PPAR-y agonists on the expression of these proteins in sy-
novial fibroblasts. Western blots showed that TNF-IX induced 
phosphorylation of p38, and expression of p38, C/EBP- j3 and 
p65 unit of NF-KB (Figure 3). Genistein, but not the com-
monly used concentrations (10/lM) of rosiglitazone or 
PGD2, downregulated TNF-IX-induced p38 phosphorylation 
and both endogenous and TNF-IX-induced p38, C/EBP-j3 and 
p6S (Figure 3). 
Genistein has been shown earlier not to change TNF-IX-
induced p65/DNA binding but to inhibit NF-KB transacti-
vation.20 Our results, obtained by the Ch1P assay, also 
showed that genistein did not prevent TNF-IX-induced 
binding of p6S to IL-8 (Figure 3b). However, genistein 
prevented CIEBP-j3 binding to IL-8 (Figure 3b) and IL-6 
promoters (results not shown). These results suggested that 
genistein inhibition of TNF-IX-induced 1L-6 and 1L-8 pro-
duction involves C/EBP-j3 transcription factor. 
Genistein and Rosiglitazone Induce Synovial Fibroblast 
Adipogenesis in Synergism 
Genistein was shown to be' a PPAR_yI4 and estrogen receptor 
(ER) 15 inducer, as weIl as an inhibitor of protein tyrosine 
kinases.21 To test the involvement of PPAR-y in genistein-
induced adipogenesis, ceUs were treated simultaneously with 
genistein and synthetic PPAR-y agonist, rosiglitazone. 
Compared with cultures treated with genistein and rosigli-
tazone alone, the numbers of oil-red-stained droplets in 
combined cultures were increased markedly (Figure 4a). 
Moreover, ELISA and western blots showed that the expres-
sion of adipocyte-specific markers, adiponectin and perili-
pin-A, were both markedly increased when genistein and 
rosiglitazone were applied simultaneously (Figure 4b and cl. 
The expression ofPPAR-y2 also increased when both agonists 
were applied simultaneously (Figure 4c). These results 
suggested that genistein and rosiglitazone act in synergism on 
synovial adipogenesis through the PPAR-y pathway. 
To test the involvement of ERs on synovial fibroblast 
adipogenesis, cens were treated with 17 -j3-estradiol, which 
did not induce synovial fibroblast adipogenesis and did 










































Figure 6 Genistein downregulates dexamethaso~e-induced leptin and its receptor and ERK1/2 phosphorylation. (a-d) Synovial fibroblasts were cultured in 
the presence of genistein (50 )lM) or dexamethasone (1 )lM) or both substances simultaneously, for 4 weeks. (Panel a) Oil-red-stained cells. Photos were 
taken under an inverse microscope at magnification x 40. (Panel b) ELISA measured adiponectin production in cell supernatant. (Panel c) ELISA measured 
leptin production in cell supernatant. *A, statistically different from control cells; *B, statistically different from genistein- and dexamethasone-treated cells; 
*C, statistically different from dexamethasone-treated cells. (Panel d) Western blot showing leptin receptor (Ob-R) expression. ERK 1/2 expression was used 
as control. (e and f) Synovial fibroblasts were cultured in the presence of genistein (50 )lM), or glucocorticoid (1 )lM) or both substances simultaneously, for 4 
weeks. Synovial fibroblast were provided by OA (panel el and RA (panel f) patients. Western blots are showing ERK1/2 phosphorylation. ERK 112 expression 
was used as control. 
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Figure 7 Glucocorticoids induce rapid leptin production in synovial 
fibroblasts. ELISA measured leptin production in cell supernatant. Synovial 
fibroblasts were cultured in the presence of dexamethasone (1 )lM), 
prednisolone (1 )lM) or cortisone (1 )lM) for the time indicated. 
The involvement of protein tyrosine kinase inhibition on 
genistein-induced adipogenesis was tested using the genistein 
non-active analog, daidzein. Although daidzein was able to 
induce some fat drop lets in synovial fibroblasts (results not 
818 
shown), its effect on adiponectin production was negligible 
compared with genistein (Figure Sb). These results suggested 
that, in addition to PPAR-y, genistein-induced adipogenesis 
involves tyrosine kinase inhibition. 
The involvement of anti-oxidant effects on genistein-induced 
adipogenesis was tested using NAC, which when applied alone, 
did not have an adipogenic effect on synovial fibroblasts 
(Figure Se). Furthermore, it significantly inhibited genistein-
induced adipogenesis (Figure Sc), suggesting that genistein-in-
duced adipogenesis does not involve its anti-oxidant properties. 
Genistein Downregulates Glucocorticoid-Induced Leptin 
Production 
Glucoeorticoids are widely used for the treatment of rheu-
matie diseases and are also known to be adipogenic in vivo 
and in vitro. Surprisingly, dexamethasone alone induced 
adipogenic transformation of only a few synovial fibroblasts 
and small amount of adiponectin (Figure 6a and b, respec-
tively) but markedly induced leptin production (Figure 6c) 
and leptin receptor (Ob-R) expression (Figure 6d). Leptin 
production was already detected after 48 h of dexamethasone 




































Figure 8 Genistein downregulates glucocorticoid-induced leptin in the 
presence of TNF-ex. (a-cl Synovial fibroblasts were stimulated with 
prednisolone (1 l'Ml in the presence or absence of TNF-ex (lOng/mI) or TNF-
ex and genistein (50 l'Ml, for 1 week. ELISA measured (panel a) lL-6, (panel b) 
IL-8 and (panel cl leptin production in cell supernatant. *A, statistîcally 
different frorn TNF-ex-treated cells; *B, statistically different frorn control 
cells; *C, statistically different frorn TNF-O(- and prednisolone-treated cells; 
*0, statistically different frorn prednisolone-treated cells. 
treatment and increased daily (Figure 7). Similar results were 
obtained with prednisolone and cortisone (Figure 7). 
Genistein markedly enhanced dexamethasone-induced adi-
pogenesis (Figure 6a and b). Of interest, in parallel, genistein 
downregulated dexamethasone-induced leptin production 
(Figure 6c) and leptin receptor expression (Figure 6d). 
Furthermore, genistein was able to downregulate gluco-
corticoid-induced leptin in the presence of TNF-IX 
(Figure 8c). In addition, genistein combined with pre-
dnisolone further inhibited TNF-IX-induced 1L-6 and 1L-8 
compared with prednisolone alone (Figure 8a and b, re-
spectively). Genistein also downregulated both endogenous 
and glucocorticoid-induced ERKl!2 phosphorylation (Figure 
6e and f). Inhibitor of the Janus kinase-2 (JAK-2) tyrosine 
kinase, tyrphostin AG 490, but not the commonly used 
concentration of PPAR-y agonist, rosiglitazone (lO/lM), 
(results not shown), inhibited prednisolone-induced leptin 
(Figure 9a). Moreover, western blot showed an increased 
tyrosine phosphorylation in the extract of dexamethasone-
and prednisolone-treated synovial fibroblasts (Figure 9b). 
Genistein inhibited dexamethasone- and prednisolone-in-
duced tyrosine phosphorylation (Figure 9b). These results 
suggested that genistein anti-Ieptin effect mainly involves 
tyrosine kinase inhibition. 
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Figure 9 JAK-2 tyrosine kinase inhibitor rnirnics the anti-Ieptin effect of 
genistein and genistein inhibits prednisolone-induced tyrosine 
phosphorylation. (a) Synovial fibroblasts were stirnulated with genistein 
(50 l'Ml or JAK-2 inhibitor tyrphostin AG 490 (50 l'Ml in the presence or 
absence of prednisolone (1 ,uM) for 1 week. ELISA rneasured leptin 
production in cell supernatant. *A, statistically different from prednisolone-
treated cells. (b) Synovial fibroblasts were stirnulated with genistein 
(50 l'Ml, dexarnethasone (1 l'Ml, prednisolone (1 l'Ml or with genistein and 
each glucocorticoid sirnultaneously for 3 weeks. Western blot shows 
tyrosine phosphorylation in total synovial fibroblast extracts. ERK 1/2 
expression was used as control. 
DISCUSSION 
Very recently, synovial fibroblasts were recognized as multi-
potent mesenchymal stem cells that express stem cell 
markers3,7 and can differentiate into chondrocytes, osteo-
blasts and adipocytes.3- 6 Usually, synovial fibroblast adipo-
genesis was induced using a mixture of substances, including 
methyl-isobutylxanthine and indomethaciné or insulin, 
dexamethasone and troglitazone.4 ,6 These adipocyte-like 
cultures4,6 expressed to a lesser degree the proinflammatory 
cytokines, 1L-6 and IL-8, and the adipogenesis of synovial 
fibroblasts has been proposed as an anti-inflammatory tool 
for combating rheumatoid diseases.6 However, the same work 
showed that TNF-IX inhibited synovial fibroblast adipogenesis, 
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suggesting limiting effects of adipogenic substances in in-
flammatory conditions. Therefore, we tested the effects of 
PPAR-y agonists on both synovial fibroblast adipogenesis and 
TNF-Cé-induced IL-6 and IL-8 production. 
Our results sbowed that in the limited conditions (DMEM 
medium supplemented with charcoal-stripped FBS and not 
by any mixture of adipocyte inducing substances), genistein 
and rosiglitazone were able to transform synovial fibroblasts 
into adipocytes characterized by oil-red-stained droplets and 
adiponectin production. In contrast, the endogen PPAR-y 
agonist precursor, PGD2, induced the transformation of sy-
novial fibroblasts into adipocytes characterized by sebum-like 
droplets and leptin production. These resuIts suggested that 
different PPAR-y agonists may differently induce PPAR-y.22 
Furthermore, we showed that genistein, but not PGD2, 
downregulated endogenous and TNF-Cé-induced 1L-6 and 
IL-8. Rosiglitazone, when applied at high concentrations 
(50 pM), had a significant but an inferior inhibitory effect on 
TNF-Cé-induced IL-6 production compared with genistein, 
which also inhibited both endogenous and TNF-(X-induced 
CIEBP-/1, a transcription factor involved in inflammation23 
and adipocyte differentiation,24 as weIl as p65 unit ofNF-KB. 
Promoters of IL-6 and IL-8 have binding sites for both CI 
EBP-/1 and NF_/(B,18,19 and functional and physical associa-
tions between NF-KB and C/EBP have been shown.25 The 
inhibitory effect of genistein on NF-KB-mediated transcrip-
tion of IL-6 has been shown20 and we have presented, in this 
study, that genistein inhibits the binding of C/EBP-/1 on the 
IL-8 promoter. These results suggest that genistein inhibits 
TNF-Cé-induced expression of IL-6 and IL-8 through the in-
hibition of NF-KB and C/EBP-/1 transcription factors. The 
inhibitory effect of genistein on 1L-17-induced IL-8 had al-
ready been observed in synovial fibroblasts?6 Consequently, 
genistein has been suggested as a substance that has anti-
inflammatory potential in tbe treatment of rheumatic dis-
eases. 26,27 However, although genisteiri downregulates TNF-(X 
inflammatory effects, it stiU cannot induce adipogenesis in 
the presence of TNF-Cé. These resuIts suggest that TNF-Cé-
induced inflammatory and anti-adipogenic pathways are at 
least partiaUy distinct. 
Although genistein enhanced the adipogenesis of osteo-
progenitor K5483 ceUs and mouse bone marrow ceIls,14,28 it 
is also described as an inhibitor of adipocyte differentiation 
of mouse 3T3-U 29-31 cells. Furthermore, genistein decreased 
the adipogenic differentiation and maturation of bone mar-
row stromal cells, and stimulated their differentiation into 
osteoblasts. 32 These differences have been explained by the 
genistein differential effects on ER and PPAR-y pathways.14,28 
Indeed, the genistein-enhanced osteogenesis of osteopro-
genitor KS483 cells is ER-mediated, whereas the genistein-
enhanced adipogenesis of osteoprogenitor KS483 cells and 
mouse-bone marrow cells is PPAR-y-mediated. 14,28 Our re-
sults showed that genistein induced adipogenesis in synergy 
with synthetic PPAR-y agonist, rosiglitazone. This synergy 
was observed in the number of adipocytes generated, perili-
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pin-A production and PPAR-y2 expression. Furthermore, 
genistein inhibited ERKl/2 phosphorylation, which 
may consequently inhibit PPAR-y2 phosphorylation, and 
enhanced adipogenesis, as shown earlier.33 In contrast to 
genistein, 17-/1-estradiol had no significant effect on synovial 
fibroblast adipogenesis, whereas genistein analog and non-
active inhibitor of protein tyrosine kinase, daidzein, had 
negligible adipogenic activities. These results suggest that 
genistein-induced adipogenesis in synovial fibroblasts 
involves PPAR-y induction and protein tyrosine kinase 
inhibition. 
Our results have shown that glucocorticoids stimulated 
leptin production in synovial fibroblasts. It was shown re-
cently in vivo, in animaIs and in humans, that glucocorticoid-
induced osteoporosis has been linked to leptin produc-
tion.34,35 In view of the known properties of leptin on bone 
metabolism, it is tempting to speculate that corticosteroid 
exposure, leptin production and demineralization are linked 
events. Accordingly, the blockade of the leptin production 
would be favorable. We have observed that genistein adipo-
genesis was enhanced markedly by dexamethasone, but 
genistein downregulated glucocorticoid-induced leptin pro-
duction in synovial fibroblasts. Furthermore, our results 
suggest that glucocorticoid-induced leptin production in-
volves the induction of tyrosine phosphorylation, and that 
genistein downregulated leptin production hy its ability to 
inhibit protein tyrosine kinases. In addition, JAK-2 protein 
tyrosine kinase inhibitor mimicked the anti-Ieptin effect of 
genistein, suggesting that leptin production in synovial 
fibroblasts involves JAK-2. In rheumatic diseases, leptin is 
usually considered as a proinflammatory adipokine. In fact, 
leptin -deficient mice are protected from experimentally 
induced arthritis,10 and protection may include leptin effects 
on T ceIls.36 Leptin was shown to be an inducer of nitric 
oxide in chondrocytes12 and of IL-8 in synovial fibroblasts. 13 
In addition, lep tin is produced by chondrocytes in OA. lI 
Finally, an anti-leptin-based approach was proposed for the 
treatment of inflammatory and auto immune diseases. 37 
These results suggest that genistein might be heneficial to 
rheumatic diseases by downregulating leptin. 
Although the protective effect of adiponectin on ChOI1-
drocytes was shown recently,3R it was also described that 
adiponectin enhanced 1L-6 production in synovial fibro-
blasts, involving p38 and NF-KB pathways.39 Our results 
showed that genistein induced adiponectin production but 
downregulated p38, p65 and IL-6. These results suggest that 
genistein may downregulate the negative effects adiponectin 
by inhibiting p38 and NF-KB pathways. 
In vivo, PPAR-y ligands have been shown to be effective in 
several mouse models of inflammation, including arthritis. 40 
Rosiglitazone improved both collagen-induced arthritis41 and 
adjuvant-induced arthritis in mice.42 Genistein-treated and 
collagen II immunized mice showed milder inflammation 
and joint destruction.43 In vitro, we have shown that, unlike 
rosiglitazone and PGD2, genistein had both adipogenic and 





Figure 10 Summary scheme of genistein effects on synovial fibroblasts. In 
summary, genistein may have several antHnflarnmatory effects on synovial 
fibroblasts: (a) through inhibition of TNF-a-induced IL-6 and IL-8 (Figure 2c 
and dl; (b) through leptin inhibition (Figure 8c); and (cl through the 
induction of adipogenesis that may per se speed down synovial fibroblast 
proliferation (Figures 1 band 4a). (d) ln addition, in concomitant treatment 
of synovial fibroblasts with glucocorticoid, genistein enhanced 
adipogenesis (Figure 4a), and downregulated leptin (Figure 6c), whereas 
TNF-C(-induced IL-6 and IL-8 are further downregulated compared with 
glucocorticoid effect without genistein (Figure 6a and b). 
anti-inflammatory properties on synovial fibroblasts. 
Furthermore, we have shown that genistein downregulated 
glucocorticoid-induced lep tin production and leptin receptor 
expression in synovial fibroblasts while having additive anti-
inflammatory properties. For these reasons, genistein may 
have a potential lor arthritis treatment in association with 
glucocorticoids or not. A schematic illustration of multiple 
anti-inflammatory effects of genistein on synovial fibroblasts 
is shawn in Figure 10. 
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